Lauko, Adam
Kotecha, Rupesh
Barnett, Addison
Li, Hong
Tatineni, Vineeth
Ali, Assad
Patil, Pradnya
Mohammadi, Alireza M.
Chao, Samuel T.
Murphy, Erin S.
Angelov, Lilyana
Suh, John H.
Barnett, Gene H.
Pennell, Nathan A.
Ahluwalia, Manmeet S.
Article History
Received: 19 May 2021
Accepted: 6 August 2021
First Online: 13 September 2021
Change Date: 17 January 2022
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41598-022-05489-0
Competing interests
: Manmeet S. Ahluwalia: Receipt of grants/research supports: Astrazeneca, Abbvie, BMS, Bayer, Incyte, Pharmacyclics, Novocure, Merck, Mimivax, Novartis, Roswell Park Cancer Foundation, Velosano. Stock shareholder: Cytodyn, Doctible, Mimivax, Medinnovate Advisors LLC. Receipt of honoraria or consultation fees: Abbvie, AstraZeneca, BMS, Flatiron, Varian Medical Systems, Bayer, Cellularity, Elsevier, Forma therapeutics. GSK, Insightec, karyopharm, Kiyatec, Novocure Inc, Tocagen, VBI Vaccines, Wiley, Xoft, Nuvation, SDP Oncology, Appollomics, Prelude, Janssen. Rupesh Kotecha: Receipt of honoraria or consultation fees: Elsevier, Elekta AB, Accuray Inc, Novocure Inc, and Viewray Inc. Research funding from Medtronic Inc., Blue Earth Diagnostics, Novocure Inc., AstraZeneca, Exelixis, and Viewray Inc. Samuel Chao: Honorarium from Varian Medical Systems and research support from Blue Earth Diagnostics. Nathan A. Pennell: BMS, Merk, Astrazeneca, Eli Lilly, Inivata, Pfizer, Amgen, Mirati, Genentech, Xencor, Janssen, Viosera, G1 Therapeautics. Gene H. Barnett: consultant for Monteris Medical Inc, royalty interests for Roche. Alireza M. Mohammadi: consultant for Monteris Medical Company. John H. Suh: consultant for Neutron Therapeutics, Novocure Inc., Philips. Adam Lauko, Addison Barnett, Vineeth Tatineni, Assad Ali, Pradnya Patil, Erin S. Murphy, Lilyana Angelov, and Hong Li all declare no conflict of interest.